A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination With Systemic Corticosteroids as First-Line Therapy in Subjects With Chronic Graft Versus Host Disease (cGVHD)
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Entospletinib (Primary) ; Corticosteroids
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 27 Feb 2017 Planned End Date changed from 1 May 2019 to 1 Aug 2019.
- 27 Feb 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Feb 2019.
- 28 Oct 2016 Planned End Date changed from 1 Apr 2020 to 1 May 2019.